The company could provide some context around the Vactosertib / CORE NK combo trial results by highlighting our ARMOURED NK Cell program which is in the lab. Vactosertib vs ARMOURED CORE-NK cells is potentially the significant differentiator here between blood cancers and solid tumours (or at least colorectal cancer). Both offer TGF-β inhibition, suppression of and persistence within the tumour microenvironment (TME).
So, whilst the Vacto combo trial is only offering efficacy in AML patients, this could be a boon for CHM-0301 (based on my research via GROK). Is our ARMOURED CORE_NK Cells therapy superior to Vactosertib? Time and data will tell. Thus far, though, our CORE-NK Cells are proving safe and in combo with Vacto they are potentially doing their job of (naturally) killing AML cancer cells and giving patients longevity.
CHM Price at posting:
0.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)